Akebia Therapeutics, Inc. Announces Presentation of Clinical Data at Kidney Week 2011
CINCINNATI--(BUSINESS WIRE)--Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced the presentation of clinical data on lead candidate AKB-6548 at American Society for Nephrology’s Kidney Week, November 8-13, 2011, in Philadelphia. AKB-6548 is an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD) inhibitor designed to increase the natural production of erythropoietin (EPO) and cause a controlled, gradual rise in hemoglobin in anemic patients. The data highlight results from a Phase 1b and 2a study on AKB-6548 for the treatment of anemia associated with chronic kidney disease.